Full Description
"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health
Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development.
Features:
Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies
Lessons-learned from successful Precision Medicine case studies
A variety of exciting and emerging biomarker technologies
The next frontiers and future challenges of biomarkers in Precision Medicine
Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings's College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.
Contents
Introduction. What is a Biomarker and its Role in Drug Development? Biomarkers in Discovery and PreClinical Safety. Translating From Pre-Clinical Results to Clinical and Back. Biomarkers in Clinical Trials -Design Considerations for Biomarker Informed Clinical Trials. The road ahead: Identification of the hurdles and solutions to the implementation of personalized medicine in healthcare. Lessons from the past and pioneers of the future. Paving a new era of personalized medicine: Emerging technologies. The next frontiers of therapeutic target areas: Autoimmunity, inflammation, respiratory, metabolic, cardiovascular and neurological diseases. Lessons Learned: What have we learned and what is the next challenge?
